Advanced search
Start date

Evaluation of cetuximab-modified porous silicon nanoparticles as docetaxel carrier to prostate cancer treatment

Grant number: 22/02661-3
Support Opportunities:Scholarships abroad - Research Internship - Post-doctor
Effective date (Start): April 01, 2023
Effective date (End): February 26, 2024
Field of knowledge:Engineering - Materials and Metallurgical Engineering
Principal Investigator:Marlus Chorilli
Grantee:Rafael Miguel Sábio
Supervisor: Helder Almeida Santos
Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Research place: University Medical Center Groningen (UMCG), Netherlands  
Associated to the scholarship:18/25377-3 - Potential evaluation of cetuximab-modified mesoporous silica nanoparticles as docetaxel carrier to prostate cancer treatment., BP.PD


Prostate cancer (PCa) is one of the most non-contagious diseases that affects the male population in the world. Although clinically effective, the chemotherapy treatment with docetaxel (DTX) is associated with the development of resistance in more advanced stages of the disease. Besides, DTX presents low aqueous solubility and drawbacks related to its pharmacokinetics. Porous silicon nanoparticles (PSi) have attracted great interest due to their biocompatibility, high chemical stability, large surface area and tunable pore diameters and volumes, allowing the incorporation of large amounts of drugs, protecting them from deactivation and degradation processes besides avoids premature release acting as an excellent nanocarrier. In addition, the hydroxyls groups available on its surface allow the conjugation of molecules such as the monoclonal antibody cetuximab (CTX) which binds to the overexpressed Enhanced Growth Factor Receptor (EGFR) in many prostate tumors, representing a potential strategy for the treatment of prostate cancer associated to DTX. Taking into account all aforementioned, the goal of this proposal is to design smart PSi-based nanoplatforms containing DTX inside the pores functionalized with CTX to PCa treatment. This proposal aims to overcome drawbacks as low internalization, premature release before to reach the target site, several side effects to the patient and low effectiveness of the current treatments. In order to evaluate these parameters, materials characterization and methods validation will be carried out as well as in vitro assays using PC-3 and DU145 cells line models and in vivo assays from animal model aiming to prove the efficacy of the new smart nanocarriers. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.